-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34

Benzinga·10/07/2026 17:23:03
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $34.